Mizuho lowered shares of Evolus (NASDAQ:EOLS) from a buy rating to a neutral rating in a report released on Tuesday morning, AnalystRatings.com reports. Mizuho currently has $3.00 target price on the stock, down from their previous target price of $8.00.
Several other equities analysts have also weighed in on EOLS. HC Wainwright reduced their price target on shares of Evolus from $15.00 to $7.00 and set a buy rating for the company in a research report on Tuesday. SunTrust Banks lowered their price target on shares of Evolus from $18.00 to $12.00 and set a buy rating on the stock in a report on Tuesday, May 12th. Wells Fargo & Co reduced their price objective on Evolus from $10.00 to $5.00 and set an equal weight rating for the company in a report on Thursday, April 30th. SVB Leerink decreased their target price on Evolus from $25.00 to $15.00 and set an outperform rating for the company in a research report on Friday, April 3rd. Finally, Barclays dropped their price target on Evolus from $9.00 to $4.00 and set an underweight rating on the stock in a research report on Wednesday, May 13th. Two analysts have rated the stock with a sell rating, three have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of Hold and a consensus price target of $11.88.
EOLS stock opened at $3.03 on Tuesday. The company has a quick ratio of 5.02, a current ratio of 5.58 and a debt-to-equity ratio of 1.24. The firm has a market cap of $112.99 million, a PE ratio of -0.89 and a beta of 3.19. The business has a 50 day moving average of $5.05 and a 200-day moving average of $6.86. Evolus has a 12-month low of $3.00 and a 12-month high of $20.27.
Large investors have recently bought and sold shares of the business. BNP Paribas Arbitrage SA boosted its holdings in shares of Evolus by 209.0% in the first quarter. BNP Paribas Arbitrage SA now owns 6,776 shares of the company’s stock worth $28,000 after acquiring an additional 4,583 shares during the period. Royal Bank of Canada lifted its holdings in Evolus by 55.6% during the 1st quarter. Royal Bank of Canada now owns 7,141 shares of the company’s stock worth $30,000 after purchasing an additional 2,553 shares in the last quarter. Edge Wealth Management LLC boosted its stake in Evolus by 325.0% in the 1st quarter. Edge Wealth Management LLC now owns 8,500 shares of the company’s stock worth $36,000 after purchasing an additional 6,500 shares during the period. Ironwood Investment Counsel LLC bought a new position in Evolus in the 1st quarter worth about $42,000. Finally, JNB Advisors LLC purchased a new position in Evolus during the 1st quarter valued at about $46,000. Hedge funds and other institutional investors own 42.43% of the company’s stock.
Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Featured Article: What is the NASDAQ?
Receive News & Ratings for Evolus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolus and related companies with MarketBeat.com's FREE daily email newsletter.